JAK inhibitors and other oral immunology drugs on Humana Premier Rx Plan (S5884-217)
Rinvoq, Xeljanz, Olumiant and Otezla, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), New York
- Premium
- $173.60/month
- Deductible
- None
1 of 5 JAK inhibitors is covered on this plan. It requires prior authorization.
4 aren't on the formulary, including Xeljanz and Olumiant.
- from $2,085.81Tier 5
Not on the formulary
Xeljanz, Olumiant, Otezla, Sotyktu
Patient cost for a 30-day supply at a preferred retail pharmacy. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.